NKGN · As filed with the SEC
NKGen Biotech cash flow statement, by quarter
The statement as NKGen Biotech presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS · USD thousands
| USD thousands | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024† 3 months ended Sep 30, 2024 | Q2 2024† 3 months ended Jun 30, 2024 |
|---|---|---|---|---|
| Operating activities | ||||
| Net income (loss) | 15,350 | (29,414)† | 6,598† | (16,088)† |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||||
| Depreciation and amortization | 341 | 295† | 297† | 294† |
| Stock-based compensation | 707 | 835† | 1,093† | 1,097† |
| Amortization of right-of-use asset | 38 | 36† | 35† | 32† |
| Noncash lease expense | — | 0† | 0† | 0† |
| Noncash interest expense (including related party amounts of $237 and $698 for the three months ended March 31, 2025 and 2024, respectively) | 403 | 188† | 293† | 545† |
| Loss on issuance of financial instruments (including related party amounts of $639 and zero for the nine months ended September 30, 2024 and 2023, respectively) | — | — | 3,990† | — |
| Gain on amendments to financial instruments, net | 0 | 710† | (999)† | 5,222† |
| Change in fair value of financial instruments (including related party amounts of $494 and $12 for the nine months ended September 30, 2024 and 2023, respectively) | — | — | (16,849)† | — |
| Loss on issuance of financial instruments (including related party amounts of zero and $74 for the three months ended March 31, 2025 and 2024, respectively) | 1,050 | — | — | — |
| Change in fair value of financial instruments (including related party amounts of $1,041 and zero for the three months ended March 31, 2025 and 2024, respectively) | (21,575) | — | — | — |
| Convertible bridge loans | (160) | — | — | — |
| Loss on sale of property and equipment, net | 0 | 0† | 0† | 1† |
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | — | 0† | 0† | 0† |
| Prepaid expenses and other current assets | (128) | (1,529)† | 193† | 402† |
| Accounts payable and accrued expenses | 1,079 | (728)† | 1,431† | (293)† |
| Other current liabilities | (25) | (378)† | 57† | 45† |
| Operating lease liability | (40) | (36)† | (34)† | (32)† |
| Other, net | 0 | — | — | 1† |
| Net cash used in operating activities | (2,800) | (6,953)† | (3,895)† | (5,999)† |
| Investing activities | ||||
| Sales of property and equipment | 0 | 0† | 0† | 0† |
| Purchases of capitalized software | (52) | (16)† | (17)† | (15)† |
| Net cash (used in) provided by investing activities | (52) | (16)† | (17)† | (15)† |
| Financing activities | ||||
| Proceeds from exercise of common stock options | — | 0† | 0† | 0† |
| Proceeds received from sales of FPA Shares | — | 1† | — | — |
| Proceeds from amendment to and settlements of FPA agreements | 0 | 0† | 1,162† | (873)† |
| Convertible Promissory Notes | 1,800 | 4,497† | 2,742† | 8,292† |
| Convertible Promissory Notes Due to Related Parties and Warrants | — | 0† | — | — |
| Convertible bridge loans | 90 | 278† | 0† | 0† |
| Proceeds from issuance of bridge notes | 0 | 0† | 0† | 0† |
| Proceeds from issuance of PIPE warrants | — | 0† | (250)† | 0† |
| Proceeds from amendment to the PIPE warrants | 0 | 0† | — | — |
| Proceeds from conversion of warrants to common stock | 11 | — | — | — |
| Proceeds from related party loans | — | 0† | 0† | 0† |
| Proceeds from draws on revolving line of credit | — | 0† | 0† | — |
| Proceeds from issuance of common stock | — | 1† | (774)† | — |
| Proceeds from capital contributions | 1,745 | — | — | — |
| Payment of revolving line of credit | (1,000) | — | — | — |
| Payment in connection with letter agreements | — | 0† | 0† | — |
| Convertible 12% Promissory Notes | — | 1† | (9)† | — |
| Convertible 12% Promissory Notes | — | 0† | (214)† | — |
| Convertible bridge loans | — | 0† | 0† | — |
| Payment of transaction costs | 0 | 0† | 40† | 0† |
| Payment of debt issuance and modification costs on revolving line of credit | — | 0† | 0† | — |
| Payment of deferred underwriting fee | — | 0† | — | — |
| Payment of bridge notes | — | 0† | 0† | — |
| Proceeds from repayments of receivables from shareholder | 0 | 0† | 0† | 0† |
| Net cash provided by financing activities | 2,646 | 6,967† | 3,820† | 6,059† |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (206) | (2)† | (92)† | 45† |
| Cash, cash equivalents, and restricted cash at the beginning of period | 235 | 237 | 329 | 284 |
| Cash, cash equivalents, and restricted cash at the end of period | 29 | 235 | 237 | 329 |
| Supplemental cash flow information | ||||
| Cash paid for interest expense | 131 | 552† | 179† | 102† |
| Supplemental disclosure of noncash investing and financing activities | ||||
| Conversion of liability classified warrants to equity pursuant to sequencing policy | — | 0† | 0† | — |
| Right-of-use asset obtained in exchange for new operating lease liability | 0 | 0† | 0† | 0† |
| Exercise of tranche right derivative | — | 0† | 0† | — |
| Initial issuance of subscription receivable | — | 1† | — | — |
| Capitalized software costs included in accounts payable and accrued expenses | 16 | 3† | 0† | 1† |
| Issuance of subscription receivable | — | 0† | (317)† | — |
| Convertible 12% Promissory Notes | — | 0† | — | — |
| Stock to Equity | — | (250)† | — | — |
| Unpaid transaction costs included in accounts payable and accrued expenses | — | 0† | 0† | 0† |
| Assumption of derivative warrant liabilities | — | 0† | — | — |
| Conversion of warrants to common stock | 760 | — | — | — |
| Conversion of convertible promissory notes to equity | 1,002 | 931† | — | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.